These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 38962827)
1. Management of liver disease and portal hypertension in cystic fibrosis: a review. Colombo C; Lanfranchi C; Tosetti G; Corti F; Primignani M Expert Rev Respir Med; 2024 May; 18(5):269-281. PubMed ID: 38962827 [TBL] [Abstract][Full Text] [Related]
2. Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. Dana J; Debray D; Beaufrère A; Hillaire S; Fabre M; Reinhold C; Baumert TF; Berteloot L; Vilgrain V J Hepatol; 2022 Feb; 76(2):420-434. PubMed ID: 34678405 [TBL] [Abstract][Full Text] [Related]
3. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)]. ; ; Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700 [TBL] [Abstract][Full Text] [Related]
4. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103 [TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis-associated liver disease. Herrmann U; Dockter G; Lammert F Best Pract Res Clin Gastroenterol; 2010 Oct; 24(5):585-92. PubMed ID: 20955961 [TBL] [Abstract][Full Text] [Related]
6. Assessment of liver disease in cystic fibrosis. Davison S Paediatr Respir Rev; 2018 Jun; 27():24-27. PubMed ID: 29933897 [TBL] [Abstract][Full Text] [Related]
9. Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. Debray D; Lykavieris P; Gauthier F; Dousset B; Sardet A; Munck A; Laselve H; Bernard O J Hepatol; 1999 Jul; 31(1):77-83. PubMed ID: 10424286 [TBL] [Abstract][Full Text] [Related]
10. Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Eldredge JA; Oliver MR; Ooi CY Paediatr Respir Rev; 2024 Jun; 50():54-61. PubMed ID: 38281822 [TBL] [Abstract][Full Text] [Related]
11. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Palaniappan SK; Than NN; Thein AW; van Mourik I Cochrane Database Syst Rev; 2020 Mar; 3(3):CD012056. PubMed ID: 32227478 [TBL] [Abstract][Full Text] [Related]
12. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. Debray D; Kelly D; Houwen R; Strandvik B; Colombo C J Cyst Fibros; 2011 Jun; 10 Suppl 2():S29-36. PubMed ID: 21658639 [TBL] [Abstract][Full Text] [Related]
14. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease. Nousia-Arvanitakis S; Fotoulaki M; Economou H; Xefteri M; Galli-Tsinopoulou A J Clin Gastroenterol; 2001 Apr; 32(4):324-8. PubMed ID: 11276276 [TBL] [Abstract][Full Text] [Related]
15. Current Treatment Options for Cystic Fibrosis-Related Liver Disease. Staufer K Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202578 [TBL] [Abstract][Full Text] [Related]